Explore the competitive landscape of Mucopolysaccharidosis I (Hurler syndrome) Therapeutics. In 2024, over 1,740 cases were diagnosed across 16 countries. With one FDA-approved drug, the pipeline ...

Explore the competitive landscape of Mucopolysaccharidosis I (Hurler syndrome) Therapeutics. In 2024, over 1,740 cases were diagnosed across 16 countries. With one FDA-approved drug, the pipeline ...

JCR Pharmaceuticals Co, a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced the launch of a film featured in The Next Frontier, a ...

Mucopolysaccharidosis type II (MPS II, or Hunter syndrome) is an X-linked recessive lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase, an enzyme that breaks down complex ...

Northern California forecast: High fire danger today and tomorrow Breezes give rise to the potential for rapid fire spread.

Expert Commentary Corneal opacities in the pediatric population pose a great challenge for corneal specialists due to the difficulties in surgical management in the pre-, intra- or post-operative ...

The indications for pediatric penetrating keratoplasty vary considerably in the literature ( Table 1 ) [9, 10, 12, 15, 16, 17, 18, 19, 20, 21] and can be classified under three broad categories ...

Every Man, Woman and Child in Guyana Must Become Oil-Minded - Column 162 Introduction Columns 159 – 161 examined the individual income statements of each ...

To optimize a gene transfer system for hematopoietic stem cell gene therapy of patients with mucopolysaccharidosis (MPS) type I, 10 retroviral vectors were constructed to express the human α-L ...

Ocular signs and symptoms including keratitis, corneal opacities, corneal irritation, corneal ulcers, conjunctivitis, eye pain, and photophobia, have been reported in patients.

COMMENT Within the literature we have found a total of six cases of bilateral corneal rings of a similar size and appearance to that which we describe; all without apparent aetiology. 1-4 In four ...